THERAPEUTIC MANAGEMENT OF DYSTHYMIA (PERSISTENT DEPRESSIVE DISORDER): LONG-TERM STRATEGIES AND REMISSION
DOI:
https://doi.org/10.56238/isevmjv5n1-022Keywords:
Persistent Depressive Disorder, Dysthymia, Therapeutic Management, Remission, Pharmacotherapy, Psychotherapy, Amantadine, Chronic ApathyAbstract
Persistent Depressive Disorder (PDD), previously known as dysthymia, is characterized by a chronic, progressive, and often treatment-resistant course, associated with significant functional impairment and continuous reduction in quality of life. This study aimed to analyze contemporary therapeutic strategies for the management of dysthymia, with an emphasis on long-term approaches and factors associated with clinical and functional remission. It is a literature review conducted through searches in PubMed and the Virtual Health Library, covering studies published in the last five years, focusing on pharmacological, psychotherapeutic, neurobiological, and technological interventions related to PDD. The analyzed studies highlight that PDD involves neurobiological alterations in subcortical structures associated with motivation and the reward system, contributing to its chronicity and limited response to conventional antidepressants. In pharmacological management, favorable evidence has been observed for the use of bupropion, lamotrigine, and, in treatment-resistant cases, amantadine, indicating promising therapeutic alternatives. The combination of pharmacotherapy and psychotherapy, especially Cognitive-Behavioral Therapy, has demonstrated greater efficacy in reducing symptoms and preventing relapses. Furthermore, psychological interventions based on digital technology showed a positive impact on quality of life improvement and ongoing treatment support. It is concluded that the management of Persistent Depressive Disorder requires an integrated, longitudinal, and individualized approach that considers the neurobiological, psychosocial, and clinical aspects involved in the chronification of the disorder. The combination of targeted pharmacological interventions, structured psychotherapy, and digital technologies constitutes a relevant strategy to promote clinical stability, sustained remission, and reduction of the functional impact of PDD.
References
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
Fursov, S., Sloeva, E., & Smirnova, D. (2025). Winston's dysthymia: Understanding the connection between childhood trauma, workplace strain, and community lack of empathy in chronic depression. Psychiatria Danubina, 37(Suppl. 1), 224–236.
Hung, C.-I., Wu, C.-T., & Chao, Y.-P. (2023). Differences in gray matter volumes of subcortical nuclei between major depressive disorder with and without persistent depressive disorder. Journal of Affective Disorders, 321, 161–166. https://doi.org/10.1016/j.jad.2022.10.025
Krzystanek, M., Martyniak, J., Palasz, A., & Krysta, K. (2023). Amantadine in treatment of dysthymia—The pilot case series study. Pharmaceuticals, 16(6), Article 897. https://doi.org/10.3390/ph16060897
MacDonald, E., & Horton, J. (2021). Bupropion for major depressive disorder or persistent depressive disorder (dysthymia). Canadian Agency for Drugs and Technologies in Health. https://doi.org/10.51731/cjht.2021.62
Matsuzaka, Y., et al. (2021). The effectiveness of lamotrigine for persistent depressive disorder: A case report. Neuropsychopharmacology Reports, 42(1), 121–124. https://doi.org/10.1002/npr2.12245
Morin, A., Bernard, J., Carle, G., Ponchel, A., et al. (2025). Chronic apathy following a major depressive episode: What is it? Cortex, 188, 42–52. https://doi.org/10.1016/j.cortex.2025.04.008
Schefft, C., et al. (2024). Evaluation of the internet-based intervention “Selfapy” in participants with unipolar depression and the impact on quality of life: A randomized, parallel group study. Quality of Life Research, 33, 1275–1286. https://doi.org/10.1007/s11136-024-031XX-X
Styss, N., Michel, C., Osman, N., Walger, P., Franscini, M., Traber-Walker, N., et al. (2025). Sociodemographic and clinical predictors of depression in children and adolescents at clinical high-risk for psychosis: Results of a two-year follow-up study. Journal of Affective Disorders, 382, 89–97. https://doi.org/10.1016/j.jad.2025.04.002
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
